| 山令顺,邬暾奕.美沙拉嗪联合地榆七柏汤灌肠治疗活动性溃疡性结肠炎的临床研究[J].浙江中西医结合杂志,2021,31(1): |
| 美沙拉嗪联合地榆七柏汤灌肠治疗活动性溃疡性结肠炎的临床研究 |
| Clinical study of Mesalazine combined with Diyuqibai Decoction enema in treatment of active ulcerative colitis |
| 投稿时间：2020-05-30 修订日期：2020-08-06 |
| DOI： |
| 中文关键词: 溃疡性结肠炎 美沙拉嗪肠溶片 地榆七柏汤 灌肠 炎症指标 临床疗效 |
| 英文关键词:Ulcerative colitis Mesalazin Enteric-coated Diyuqibai Decoction Enema Inflammatory factors Clinical efficacy |
| 基金项目: |
|
| 摘要点击次数: 422 |
| 全文下载次数: 5 |
| 中文摘要: |
| 摘要: 目的 探讨美沙拉嗪联合地榆七柏汤灌肠治疗活动性溃疡性结肠炎（Ulcerative Colitis，UC）的临床疗效及对血清炎症因子水平的影响。方法 回顾性选择2019年6月~2020年3月于我院就诊的84例活动性UC患者作为研究对象，随机分为对照组和观察组各42例，其中对照组口服美沙拉嗪肠溶片1g/次，4次/日，观察组在对照组的基础上给予地榆七柏汤50ml/次灌肠。两组治疗疗程均为8周。观察两组临床疗效、Baron评分、Mayo指数、血清IL-17、IL-6和TNF-a水平及不良反应发生率的差异。结果 8周后，观察组和对照组总有效率分别为95.24%和78.57%，与对照组相比，观察组总有效率显著升高（P=0.024）。8周后，与治疗前相比，两组Baron评分、Mayo指数、血清IL-17、IL-6和TNF-a水平均显著下降，差异均具有统计学意义（P<0.05）；与对照组相比，观察组Baron评分、Mayo指数、血清IL-17、IL-6和TNF-a水平均显著下降，差异均具有统计学意义（P<0.05）。治疗期间观察组和对照组不良反应发生率分别为9.52%和7.14%，两组不良反应发生率相比无显著差异（P=0.693）。结论 地榆七柏汤灌肠能显著提高美沙拉嗪治疗活动性UC的临床疗效，能迅速改善患者临床症状，可能机制与降低机体炎症因子的表达水平有关。 |
| 英文摘要: |
| Abstract: Objective To observe the clinical efficacy and serum inflammatory factors levels in patients with acute ulcerative colitis (UC) after Mesalazine combined with Diyuqibai Decoction enema treatment. Methods A total of 84 patients with acute UC from our hospital between June 2019 to March 2020 were enrolled and randomly divided into control group and observation group (42 cases in each group). Patients in the control group were po administered with Mesalazin Enteric-coated Tablets, 1g/time, four times a day. Patients in the observation group were administered with Diyuqibai Decoction enema based on the control group, 50ml/time, once a day. All patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy, Baron scores, Mayo index, serum levels of IL-17, IL-6 and TNF-a and incidence of adverse reactions between two groups were compared. Results After 8 weeks treatment, the total effective rate in the observation and control group was 95.24% and 78.57%, respectively. When compared with the control group, the total effective rate in the observation group was significantly higher (P=0.024). After 8 weeks treatment, the Baron scores, Mayo index and serum levels of IL-17, IL-6 and TNF-a in two groups were significantly lower than those in before treatment (P<0.05). When compared with the control group, the Baron scores, Mayo index and serum levels of IL-17, IL-6 and TNF-a in observation group were significantly lower (P<0.05). The incidence of adverse reactions in two groups was 9.52% and 7.14%, respectively.There was no significant difference in the incidence of adverse reactions in two groups (P>0.05). Conclusions Diyuqibai Decoction enema can significantly improve the clinical efficacy of Mesalazine in the treatment of active UC, and can rapidly ameliorate the clinical symptoms, which may be related to the reduction of the inflammatory factors levels. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
